Barbara Mason

Title(s)Adjunct Professor, Psychiatry
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Examining the Role of Circulating Endocannabinoids in Predicting Alcohol Relapse Risk and Resiliency
    NIH R21AA028321Apr 10, 2020 - Mar 31, 2022
    Role: Principal Investigator
    Proof-of-Concept Human Laboratory Testing of Novel Drug Candidates Identified by INIA-NeuroImmune
    NIH U01AA025476Feb 1, 2017 - Jan 31, 2022
    Role: Principal Investigator
    Recent Frontiers and Advances in Drug Addiction (IDARS Conference)
    NIH R13DA040432Aug 1, 2015 - Jul 31, 2016
    Role: Principal Investigator
    Glucocorticoid Antagonist Treatment of Alcohol Use Disorder
    NIH R01AA023152Sep 1, 2014 - Dec 31, 2019
    Role: Principal Investigator
    Pharmacological Treatment of Cannabis Withdrawal and Dependence
    NIH R01DA030988Sep 30, 2010 - Jan 31, 2017
    Role: Principal Investigator
    Gabapentin Treatment of Cannabis Dependence
    NIH R01DA026758Jul 15, 2009 - May 31, 2016
    Role: Principal Investigator
    TRANSLATIONAL CTR ON THE CLINICAL NEUROBIOL OF CANNABIS ADDICTION
    NIH P20DA024194Sep 30, 2007 - Jun 30, 2012
    Role: Principal Investigator
    Gabapentin for Cannabis Withdrawal and Use
    NIH R21DA020766May 1, 2006 - Oct 30, 2008
    Role: Principal Investigator
    Duloxetine versus Pregabalin for Treatment of Alcohol Dependence
    NIH R37AA014028Mar 1, 2003 - Aug 31, 2014
    Role: Principal Investigator
    Medication Development for Protracted Abstinence in Alcoholism
    NIH R01AA012602Sep 25, 1999 - Jun 30, 2017
    Role: Principal Investigator
    BEHAVIORAL/PHARMACOLOGIC TREATMENT OF ALCOHOLISM
    NIH U10AA011727Sep 30, 1997 - Aug 31, 2005
    Role: Co-Principal Investigator
    NALMEFENE IN NICOTINE AND ALCOHOL DEPENDENCE
    NIH R01AA011210Sep 29, 1996 - May 31, 2005
    Role: Principal Investigator
    NALMEFENE MAINTENANCE TREATMENT OF ALCOHOLISM
    NIH R01AA010518Apr 1, 1995 - Mar 31, 2002
    Role: Principal Investigator
    NALMEFENE MODIFICATION OF ALCOHOLISM
    NIH R01AA009560Sep 30, 1992 - Aug 31, 1996
    Role: Principal Investigator
    DESIPRAMINE METABOLISM IN RECOVERING ALCOHOLICS
    NIH R01AA008111Jan 1, 1990 - Dec 31, 1993
    Role: Principal Investigator
    LONGTERM ANTIDEPRESSANT TREATMENT OF ALCOHOLISM
    NIH R23AA006866Mar 1, 1987 - Feb 28, 1991
    Role: Principal Investigator
    CNS Effects of Alcohol: Cellular Neurobiology
    NIH P60AA006420Dec 1, 1983 - Dec 31, 2022
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A reverse translational study of PPAR-α agonist efficacy in human and rodent models relevant to alcohol use disorder. Neurobiol Stress. 2024 Mar; 29:100604. Mason BJ, Estey D, Roberts A, de Guglielmo G, George O, Light J, Stoolmiller M, Quello S, Skinner M, Shadan F, Begovic A, Kyle MC, Harris RA. PMID: 38292518; PMCID: PMC10825428.
      View in: PubMed   Mentions:
    2. Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats. Front Pharmacol. 2023; 14:1127735. Illenberger JM, Flores-Ramirez FJ, Matzeu A, Mason BJ, Martin-Fardon R. PMID: 37180716; PMCID: PMC10172671.
      View in: PubMed   Mentions: 1  
    3. Preclinical and clinical evidence for suppression of alcohol intake by apremilast. J Clin Invest. 2023 03 15; 133(6). Grigsby KB, Mangieri RA, Roberts AJ, Lopez MF, Firsick EJ, Townsley KG, Beneze A, Bess J, Eisenstein TK, Meissler JJ, Light JM, Miller J, Quello S, Shadan F, Skinner M, Aziz HC, Metten P, Morrisett RA, Crabbe JC, Roberto M, Becker HC, Mason BJ, Ozburn AR. PMID: 36656645; PMCID: PMC10014105.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCTClinical Trials
    4. Alternative use of suvorexant (Belsomra®) for the prevention of alcohol drinking and seeking in rats with a history of alcohol dependence. Front Behav Neurosci. 2022; 16:1085882. Flores-Ramirez FJ, Illenberger JM, Pascasio GE, Matzeu A, Mason BJ, Martin-Fardon R. PMID: 36620860; PMCID: PMC9813433.
      View in: PubMed   Mentions: 3  
    5. Looking Back, Looking Forward: Current Medications and Innovative Potential Medications to Treat Alcohol Use Disorder. Alcohol Res. 2022; 42(1):11. Mason BJ. PMID: 36320345; PMCID: PMC9595448.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    6. Alcohol dependence and withdrawal increase sensitivity of central amygdalar GABAergic synapses to the glucocorticoid receptor antagonist mifepristone in male rats. Neurobiol Dis. 2022 03; 164:105610. Khom S, Rodriguez L, Gandhi P, Kirson D, Bajo M, Oleata CS, Vendruscolo LF, Mason BJ, Roberto M. PMID: 34995754; PMCID: PMC9301881.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    7. Neuropsychological performance in young adults with cannabis use disorder. J Psychopharmacol. 2021 11; 35(11):1349-1355. Selamoglu A, Langley C, Crean R, Savulich G, Cormack F, Sahakian BJ, Mason B. PMID: 34694178; PMCID: PMC8600580.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    8. Alcohol Use Disorder: The Role of Medication in Recovery. Alcohol Res. 2021; 41(1):07. Mason BJ, Heyser CJ. PMID: 34113531; PMCID: PMC8184096.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    9. Medications to Treat Alcohol Use Disorder: Targeting the Dark Side. Am J Psychiatry. 2021 05 01; 178(5):375-377. Mason BJ. PMID: 33979539.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Glucocorticoid receptor modulators decrease alcohol self-administration in male rats. Neuropharmacology. 2021 05 01; 188:108510. McGinn MA, Tunstall BJ, Schlosburg JE, Gregory-Flores A, George O, de Guglielmo G, Mason BJ, Hunt HJ, Koob GF, Vendruscolo LF. PMID: 33647278; PMCID: PMC8099171.
      View in: PubMed   Mentions: 14     Fields:    Translation:Animals
    11. Effects of Tacrolimus and Other Immune Targeting Compounds on Binge-Like Ethanol Drinking in High Drinking in the Dark Mice. Neurosci Insights. 2020; 15:2633105520975412. Grigsby KB, Savarese AM, Metten P, Mason BJ, Blednov YA, Crabbe JC, Ozburn AR. PMID: 33294845; PMCID: PMC7705291.
      View in: PubMed   Mentions: 3  
    12. The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug Alcohol Depend. 2020 07 01; 212:107993. Loflin MJE, Kiluk BD, Huestis MA, Aklin WM, Budney AJ, Carroll KM, D'Souza DC, Dworkin RH, Gray KM, Hasin DS, Lee DC, Le Foll B, Levin FR, Lile JA, Mason BJ, McRae-Clark AL, Montoya I, Peters EN, Ramey T, Turk DC, Vandrey R, Weiss RD, Strain EC. PMID: 32360455; PMCID: PMC7293929.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    13. The future of translational research on alcohol use disorder. Addict Biol. 2021 03; 26(2):e12903. Ray LA, Grodin EN, Leggio L, Bechtholt AJ, Becker H, Feldstein Ewing SW, Jentsch JD, King AC, Mason BJ, O'Malley S, MacKillop J, Heilig M, Koob GF. PMID: 32286721; PMCID: PMC7554164.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    14. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. Alcohol Clin Exp Res. 2019 01; 43(1):158-169. Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, Burns H, Salloum IM, Newport DJ, Mendelson J, Galloway G, Kampman K, Brooks C, Green AI, Brunette MF, Rosenthal RN, Dunn KE, Strain EC, Ray L, Shoptaw S, Ait-Daoud Tiouririne N, Gunderson EW, Ransom J, Scott C, Leggio L, Caras S, Mason BJ, Litten RZ, National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group. PMID: 30403402; PMCID: PMC6317996.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    15. Larry Parsons: Researcher, mentor, and friend. Addict Biol. 2018 11; 23(6):1204-1206. Frantz K, Roberto M, Mason B, Koob GF, Volkow N, Rodriguez de Fonseca F. PMID: 30485629.
      View in: PubMed   Mentions:    Fields:    
    16. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs. 2018 Jan; 27(1):113-124. Mason BJ, Quello S, Shadan F. PMID: 29241365; PMCID: PMC5957503.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimals
    17. Emerging pharmacotherapies for alcohol use disorder. Neuropharmacology. 2017 Aug 01; 122:244-253. Mason BJ. PMID: 28454983; PMCID: PMC5643030.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimals
    18. Existing and Future Drugs for the Treatment of the Dark Side of Addiction. Annu Rev Pharmacol Toxicol. 2016; 56:299-322. Koob GF, Mason BJ. PMID: 26514207.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansAnimals
    19. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest. 2015 Aug 03; 125(8):3193-7. Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, McGinn MA, Zamora-Martinez ER, Belanoff JK, Hunt HJ, Sanna PP, George O, Koob GF, Edwards S, Mason BJ. PMID: 26121746; PMCID: PMC4563748.
      View in: PubMed   Mentions: 117     Fields:    Translation:HumansAnimals
    20. Acamprosate, alcoholism, and abstinence. J Clin Psychiatry. 2015 Feb; 76(2):e224-5. Mason BJ. PMID: 25742214.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Measuring sleep disturbances in patients with alcohol use disorders: a short questionnaire suitable for routine practice. J Addict Med. 2015 Jan-Feb; 9(1):25-30. Perney P, Rigole H, Mason B, Dematteis M, Lehert P. PMID: 25629883.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    22. Gabapentin treatment for alcohol dependence--reply. JAMA Intern Med. 2014 Jul; 174(7):1201-2. Mason BJ, Goodell V, Shadan F. PMID: 25003890.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity. Addict Biol. 2015 Jul; 20(4):756-72. Araos P, Pedraz M, Serrano A, Lucena M, Barrios V, García-Marchena N, Campos-Cloute R, Ruiz JJ, Romero P, Suárez J, Baixeras E, de la Torre R, Montesinos J, Guerri C, Rodríguez-Arias M, Miñarro J, Martínez-Riera R, Torrens M, Chowen JA, Argente J, Mason BJ, Pavón FJ, Rodríguez de Fonseca F. PMID: 24854157.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimals
    24. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014 Jan; 174(1):70-7. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. PMID: 24190578; PMCID: PMC3920987.
      View in: PubMed   Mentions: 133     Fields:    Translation:Humans
    25. A translational approach to novel medication development for protracted abstinence. Curr Top Behav Neurosci. 2013; 13:647-70. Mason BJ, Higley AE. PMID: 22351425.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsPHPublic Health
    26. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012 Jun; 37(7):1689-98. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, Kyle M, Adusumalli M, Begovic A, Rao S. PMID: 22373942; PMCID: PMC3358737.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansAnimalsCTClinical Trials
    27. Sleep disturbance in alcoholism: proposal of a simple measurement, and results from a 24-week randomized controlled study of alcohol-dependent patients assessing acamprosate efficacy. Alcohol Alcohol. 2012 Mar-Apr; 47(2):133-9. Perney P, Lehert P, Mason BJ. PMID: 22218671.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    28. Treatment of alcohol dependence with drug antagonists of the stress response. Alcohol Res. 2012; 34(4):516-21. Higley AE, Koob GF, Mason BJ. PMID: 23584117; PMCID: PMC3860394.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    29. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res. 2012 Mar; 36(3):497-508. Mason BJ, Lehert P. PMID: 21895717; PMCID: PMC3288465.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    30. Craving in response to stress induction in a human laboratory paradigm predicts treatment outcome in alcohol-dependent individuals. Psychopharmacology (Berl). 2011 Nov; 218(1):121-9. Higley AE, Crane NA, Spadoni AD, Quello SB, Goodell V, Mason BJ. PMID: 21607563; PMCID: PMC3191263.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    31. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011 Mar; 5(1):1-8. Crean RD, Crane NA, Mason BJ. PMID: 21321675; PMCID: PMC3037578.
      View in: PubMed   Mentions: 233     Fields:    Translation:Humans
    32. Effects of chronic, heavy cannabis use on executive functions. J Addict Med. 2011 Mar; 5(1):9-15. Crean RD, Tapert SF, Minassian A, Macdonald K, Crane NA, Mason BJ. PMID: 21643485; PMCID: PMC3106308.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansPHPublic Health
    33. Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets. 2010 Mar; 9(1):23-32. Mason BJ, Heyser CJ. PMID: 20201812; PMCID: PMC2853976.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsPHPublic Health
    34. The effects of current subsyndromal psychiatric symptoms or past psychopathology on alcohol dependence treatment outcomes and acamprosate efficacy. Am J Addict. 2010 Mar-Apr; 19(2):147-54. Mason BJ, Lehert P. PMID: 20163387.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    35. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf. 2010 Jan; 9(1):177-88. Mason BJ, Heyser CJ. PMID: 20021295.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    36. Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trial. Am J Clin Nutr. 2010 Jan; 91(1):131-9. Reid IR, Ames R, Mason B, Bolland MJ, Bacon CJ, Reid HE, Kyle C, Gamble GD, Grey A, Horne A. PMID: 19906800.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    37. Stress, alcohol craving, and relapse risk: mechanisms and viable treatment targets. Alcohol. 2009 Nov; 43(7):541-3. Mason BJ, Shaham Y, Weiss F, Le AD. PMID: 19913197; PMCID: PMC2805701.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    38. Effects of nicotine and illicit substance use on alcoholism treatment outcomes and acamprosate efficacy. J Addict Med. 2009 Sep; 3(3):164-71. Mason BJ, Lehert P. PMID: 21769013.
      View in: PubMed   Mentions: 11     Fields:    
    39. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov. 2009 Jun; 8(6):500-15. Koob GF, Kenneth Lloyd G, Mason BJ. PMID: 19483710; PMCID: PMC2760328.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansAnimals
    40. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol. 2009 Jan; 14(1):73-83. Mason BJ, Light JM, Williams LD, Drobes DJ. PMID: 18855801; PMCID: PMC2758315.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    41. Effect of positive and negative affective stimuli and beverage cues on measures of craving in non treatment-seeking alcoholics. Psychopharmacology (Berl). 2008 Sep; 200(1):141-50. Mason BJ, Light JM, Escher T, Drobes DJ. PMID: 18604601; PMCID: PMC2758314.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    42. Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. Expert Rev Neurother. 2007 Nov; 7(11):1465-77. Mason BJ, Crean R. PMID: 17997696.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    43. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 03; 295(17):2003-17. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A, COMBINE Study Research Group. PMID: 16670409.
      View in: PubMed   Mentions: 699     Fields:    Translation:Humans
    44. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006 Aug; 40(5):383-93. Mason BJ, Goodman AM, Chabac S, Lehert P. PMID: 16546214.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    45. Understanding and treating alcohol dependence. Alcohol Clin Exp Res. 2006 Mar; 30(3):567-84. Johnson BA, Koob GF, Schuckit MA, Mason BJ, Ait-Daoud N. PMID: 16499499.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    46. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol. 2006 Feb; 26(1):13-20. Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, Anthenelli R, Brower KJ, O'Malley S, Mason BJ, Hasin D, Keller M. PMID: 16415699.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    47. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother. 2005 Oct; 6(12):2103-15. Mason BJ. PMID: 16197362.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    48. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. J Stud Alcohol Suppl. 2005 Jul; (15):148-56; discussion 140. Mason BJ. PMID: 16223066.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    49. How pilot studies improve large-scale clinical trials: lessons learned from the COMBINE Study. J Stud Alcohol Suppl. 2005 Jul; (15):66-71; discussion 65. O'Malley SS, Martin DJ, Hosking JD, Mason BJ. PMID: 16223058.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    50. Effects of calcium supplementation on body weight and blood pressure in normal older women: a randomized controlled trial. J Clin Endocrinol Metab. 2005 Jul; 90(7):3824-9. Reid IR, Horne A, Mason B, Ames R, Bava U, Gamble GD. PMID: 15827103.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    51. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur Neuropsychopharmacol. 2003 Dec; 13(6):469-75. Mason BJ. PMID: 14636963.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    52. Acamprosate. Recent Dev Alcohol. 2003; 16:203-15. Mason BJ. PMID: 12638639.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    53. Rapid and sensitive determination of nalmefene in human plasma by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 25; 773(2):143-9. Xie S, Suckow RF, Mason BJ, Allen D, Cooper TB. PMID: 12031840.
      View in: PubMed   Mentions:    Fields:    
    54. Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res. 2002 Apr; 26(4):586-92. Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR. PMID: 11981137.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    55. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Impact of Managed Pharmaceutical Care Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy. 2000 Oct; 20(10):1149-58. Malone DC, Carter BL, Billups SJ, Valuck RJ, Barnette DJ, Sintek CD, Okano GJ, Ellis S, Covey D, Mason B, Jue S, Carmichael J, Guthrie K, Sloboda L, Dombrowski R, Geraets DR, Amato MG. PMID: 11034037.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    56. Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectr. 2000 Feb; 5(2):58-69. Mason BJ, Ownby RL. PMID: 18296999.
      View in: PubMed   Mentions: 13     Fields:    
    57. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999 Aug; 56(8):719-24. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. PMID: 10435606.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    58. Medical allies against alcoholism. Health News. 1999 Jun 25; 5(8):3-4. Mason B. PMID: 10397028.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    59. Psychiatric comorbidity in methadone maintained patients. J Addict Dis. 1998; 17(3):75-89. Mason BJ, Kocsis JH, Melia D, Khuri ET, Sweeney J, Wells A, Borg L, Millman RB, Kreek MJ. PMID: 9789161.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    60. Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother. 1997 Feb; 31(2):175-7. Mason BJ, Blackburn KH. PMID: 9034418.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    61. Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology (Berl). 1996 Nov; 128(2):206-15. Johnson BA, Jasinski DR, Galloway GP, Kranzler H, Weinreib R, Anton RF, Mason BJ, Bohn MJ, Pettinati HM, Rawson R, Clyde C. PMID: 8956382.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    62. Dosing issues in the pharmacotherapy of alcoholism. Alcohol Clin Exp Res. 1996 Oct; 20(7 Suppl):10A-16A. Mason BJ. PMID: 8904989.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    63. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA. 1996 Mar 13; 275(10):761-7. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. PMID: 8598592.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    64. Women and minorities representation in alcoholism treatment research. Psychopharmacol Bull. 1996; 32(2):201-4. Williams LD, Mason BJ, Goldberg G, Cutler RB. PMID: 8783889.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    65. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994 Oct; 18(5):1162-7. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E. PMID: 7847600.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    66. Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject. Alcohol Clin Exp Res. 1994 Oct; 18(5):1187-9. Salvato FR, Mason BJ. PMID: 7847604.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    67. Desipramine in the treatment of depressed alcoholics. Am J Psychiatry. 1994 Aug; 151(8):1248. Mason BJ, Kocsis JH. PMID: 8037266.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    68. Desipramine treatment of alcoholism. Psychopharmacol Bull. 1991; 27(2):155-61. Mason BJ, Kocsis JH. PMID: 1924663.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    69. Amoxapine versus amitriptyline for continuation therapy of depression. J Clin Psychopharmacol. 1990 Oct; 10(5):338-43. Mason BJ, Kocsis JH, Frances AJ, Mann JJ. PMID: 2258450.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    70. Prediction of response of chronic depression to imipramine. J Affect Disord. 1989 Nov-Dec; 17(3):255-60. Kocsis JH, Mason BJ, Frances AJ, Sweeney J, Mann JJ, Marin D. PMID: 2529294.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    71. Imipramine and social-vocational adjustment in chronic depression. Am J Psychiatry. 1988 Aug; 145(8):997-9. Kocsis JH, Frances AJ, Voss C, Mason BJ, Mann JJ, Sweeney J. PMID: 3394886.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    72. Imipramine treatment for chronic depression. Arch Gen Psychiatry. 1988 Mar; 45(3):253-7. Kocsis JH, Frances AJ, Voss C, Mann JJ, Mason BJ, Sweeney J. PMID: 3277579.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    73. Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. J Clin Psychiatry. 1985 Aug; 46(8 Pt 2):15-9. Escobar JI, Mann JJ, Keller J, Wilkins J, Mason B, Mills MJ. PMID: 3894337.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    74. Protein intake and serum albumin levels in the elderly. Gerontology. 1977; 23(5):360-7. MacLennan WJ, Martin P, Mason BJ. PMID: 852664.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    75. The relationship of laboratory parameters to dietary intake in a long-stay hospital. Age Ageing. 1975 Nov; 4(4):189-94. MacLennan WJ, Coombe NB, Martin P, Mason BJ. PMID: 830074.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    76. Causes for reduced dietary intake in a long-stay hospital. Age Ageing. 1975 Aug; 4(3):175-80. MacLennan WJ, Martin P, Mason BJ. PMID: 1211304.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    77. Energy intake, disability, disease and skinfold thickness in a long-stay hospital. Gerontol Clin (Basel). 1975; 17(3):173-80. MacLennan WJ, Martin P, Mason BJ. PMID: 810391.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    Barbara's Networks
    Concepts (265)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (11)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California